Accessibility Skip to:
  • Accessibility Policy
  • Main Content
  • Main Menu
  • Contact

  • -A: Font Smaller
  • +A: Font Larger
  • Reset Font
  • High Contrast
  • Low Contrast
  • Reset Contrast
History:
You are here:
  • Grand Challenges Canada
  • >
  • Innovations
  • >
  • 0244-01
  • Français
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
Grand Challenges Canada

Bold Ideas with Big Impact®

Browse our Innovations and Results
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
  • Accessibility
  • Contact
  • Français

Home » Innovations » 0244-01

Nanobiosym pilot project for optimization and evaluation of the Gene-RADAR® point-of-care diagnostic device for identification of HIV treatment failure and prevention of drug-resistant HIV in Rwanda

FacebookTwitterLinked In

Start Date: 01/05/2013- End Date: 30/04/2014


Project Lead(s): Anita Goel

Issue

The emergence of drug-resistant HIV (DR-HIV) is a global health crisis, with up to 72% of patients failing HIV treatment and 6.8% of newly infected individuals now having evidence of drug-resistant HIV (World Health Organization, 2012).

Drug resistance is fueled by under-diagnosis of HIV treatment failures and resistance, which require viral load testing. Rwanda, a Sub-Saharan African country with over 150,000 individuals living with HIV, has just one facility capable of viral load testing, which is slow, costly and inaccessible. There is an urgent need for approximately 200,000 HIV viral load tests per year for Rwanda’s 42 district hospitals. 

Solution

Nanobiosym (NBS), in collaboration with its on-the-ground partners in Rwanda, introduced and piloted its proprietary Gene-RADAR® solution for the Rwandan context and demonstrated its ability in identifying HIV treatment failure, thus helping to prevent the spread of DR-HIV.

Gene-RADAR, which can detect any disease with a genetic fingerprint from a drop of blood or saliva, could transform conventional monitoring of HIV treatment, allowing for the detection of treatment failure and customization of therapy at the point of care (which would eliminate the need for costly overhead infrastructure, complex sample transport logistics and highly trained personnel). Nanobiosym’s Gene-RADAR delivers gold standard results at the point of care, at an affordable price.

Outcome

Nanobiosym successfully completed the following milestones:

1) Identified optimal performance metrics for the Gene-RADAR solution for the Rwandan context

2) The NBS ecosystem of collaborators and partners assisted in a clinical study for scale-up

3) NBS demonstrated the feasibility of the Gene-RADAR solution

Various performance metrics (such as level of user training, target price per test and turnaround time) will be used to evaluate this proof-of-concept. Gene-RADAR’s ability to detect DR-HIV strains can serve as a key deciding factor in optimizing anti-retroviral treatment regiments in patients with first-line virologic failure in a timely manner.  

Stay in touch with this innovator

  • Organization Website
  • Network Website
  • Innovation Overview
    Program

    Stars in Global Health

    Institution

    Nanobiosym

    Institution Country

    Rwanda

    Implementation Country

    Rwanda

    Implementation Region

    Sub-Saharan Africa

    Priority

    HIV, Infectious Diseases

    Platform

    Diagnostics / Diagnostics

Grand Challenges Canada’s programs are primarily undertaken with the financial support of the Government of Canada provided through Global Affairs Canada.

Government of Canada
  • Fluxx Technical Support
  • Privacy Policy
  • Website Legal Terms and Disclaimer
We use cookies on our website to give you the most relevant experience by remembering your preferences and activity on our website. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may click on "Cookie Settings" to select the cookies applicable to your activity and disable those that do not. Please note that you will not be able to disable all cookies as some are necessary for the functioning of the website.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT